PROCEPT BioRobotics (MEX:PRCT) Current Accrued Expense: MXN0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PRCT PROCEPT BioRobotics Corp MEX:PRCT
44 GF Score
Price MXN357.00
GF Value MXN1,386.73
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is PROCEPT BioRobotics Current Accrued Expense?

PROCEPT BioRobotics MEX:PRCT 44 Current Accrued Expense is MXN0 Mil as of Jun. 2026. GuruFocus rates MEX:PRCT with a GF Score™ of 44/100 and a GF Value™ of MXN1,386.73 (Significantly Undervalued). The stock has 1 warning sign investors should review.

PROCEPT BioRobotics's Current Accrued Expense for the quarter that ended in Jun. 2026 was MXN0 Mil.

PROCEPT BioRobotics's quarterly Current Accrued Expense declined from Dec. 2025 (MXN22 Mil) to Mar. 2026 (MXN0 Mil) but then stayed the same from Mar. 2026 (MXN0 Mil) to Jun. 2026 (MXN0 Mil).

PROCEPT BioRobotics's annual Current Accrued Expense increased from Dec. 2023 (MXN7 Mil) to Dec. 2024 (MXN22 Mil) but then declined from Dec. 2024 (MXN22 Mil) to Dec. 2025 (MXN22 Mil).

PROCEPT BioRobotics Current Accrued Expense Related Terms

PROCEPT BioRobotics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for PROCEPT BioRobotics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROCEPT BioRobotics Current Accrued Expense Chart

PROCEPT BioRobotics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 30.98 49.48 7.45 22.21 22.15

PROCEPT BioRobotics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 22.15 0.00 0.00
MEX:PRCT
44GF Score
PROCEPT BioRobotics Corp MEX:PRCT
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PROCEPT BioRobotics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of MXN0 Mil mean?
PROCEPT BioRobotics (MEX:PRCT) has a Current Accrued Expense of MXN0 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on PROCEPT BioRobotics and its competitors.
Is PROCEPT BioRobotics' Current Accrued Expense too high?
PROCEPT BioRobotics' current Current Accrued Expense is MXN0 Mil. Overall, PROCEPT BioRobotics has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Current Accrued Expense compare to INMD and LMRI?
PROCEPT BioRobotics' Current Accrued Expense of MXN0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on PROCEPT BioRobotics and its competitors. PROCEPT BioRobotics's current Current Accrued Expense is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (MEX:PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,386.73, compared to a current price of MXN357.00 — trading 74.3% below its estimated fair value. The current Current Accrued Expense is MXN0 Mil. PROCEPT BioRobotics' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For PROCEPT BioRobotics (MEX:PRCT), the current Current Accrued Expense is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROCEPT BioRobotics (MEX:PRCT) Overvalued in 2026?

Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued. The current stock price of MXN357.00 is trading 74.3% below its estimated GF Value™ of MXN1,386.73. GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.

Key valuation signals for MEX:PRCT:

  • Current Accrued Expense: MXN0 Mil
  • GF Value™: MXN1,386.73 vs. price of MXN357.00 (74.3% below fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the MEX:PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PROCEPT BioRobotics Business Description

Other Exchanges PRCT:USA
Address 150 Baytech Drive, San Jose, CA, USA, 95134
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
44GF Score

Get the complete analysis for MEX:PRCT

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN357.00
Price
MXN1,386.73
GF Value